EDITION:
- EU
- NA
It is not clear how the new Drugs Commissioner will react to the blistering growth of telemedicine, but it is clear that patients would suffer most should access be tightened.
In this special edition of the Business of Cannabis Podcast, we go From Anecdote to Evidence with Dr Anne
Doctors at the US Department of Veterans Affairs (VA) may soon be allowed to recommend medical cannabis to patients, following the passage of a landmark House spending bill that seeks to align federal veterans’ care with state-level cannabis laws.
Below, we’ve summarised the key insights from the vibrant and diverse discussions throughout Day 2 of Cannabis Europa 2025. If you’re keen to dive into the details, we’ll be exploring each session in more detail over the coming weeks.Â
Texas medical cannabis and hemp businesses both enjoyed some major, yet largely unexpected news over the weekend, not only ensuring the continued legality of hemp but significantly expanding the state’s medical cannabis programme.Â
Dalgety, a UK-based EU-GMP certified medical cannabis cultivator, is pleased to announce a strategic partnership with Curaleaf Laboratories, a trusted name in cannabis medicine and pharmaceutical-quality cannabinoid innovation.
Under the collaboration, Glass Pharms will supply high-quality cannabis flower for use in Mamedica-branded, clinician-prescribed products, reinforcing the value of a fully domestic supply chain for CBPMs (Cannabis-Based Products for Medicinal Use).
Ukraine has issued its first medical cannabis import permit, marking a major milestone in its treatment rollout despite war-related regulatory challenges.
Germany tightens control on online cannabis prescriptions. Court ruling bans advertising, while Health Minister calls for stricter access to medical cannabis via online platforms.
Medical cannabis clinics are often driven to scale their operations quickly, out of a desire to reach more patients who could benefit from treatment and the need to remain affordable for them. But doing so shouldn’t come at the cost of regulatory compliance.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
